BridgeBio Pharma (BBIO) PT Raised to $75 at Leerink Partners
Tweet Send to a Friend
Leerink Partners analyst Mani Foroohar raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $75.00 (from $68.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
